MX2016010699A - Composiciones y metodos para tratar neutropenia. - Google Patents
Composiciones y metodos para tratar neutropenia.Info
- Publication number
- MX2016010699A MX2016010699A MX2016010699A MX2016010699A MX2016010699A MX 2016010699 A MX2016010699 A MX 2016010699A MX 2016010699 A MX2016010699 A MX 2016010699A MX 2016010699 A MX2016010699 A MX 2016010699A MX 2016010699 A MX2016010699 A MX 2016010699A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- csf
- analog
- compositions
- retinoid agonist
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000004235 neutropenia Diseases 0.000 title abstract 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract 3
- 239000000556 agonist Substances 0.000 abstract 3
- 150000004492 retinoid derivatives Chemical class 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
Abstract
La invención se refiera a métodos para utilizar un agonista retinoide y un G-CSF o análogo de este para tratar, prevenir, reducir la probabilidad de tener, reducir la gravedad y/o enlentecer la evolución de una afección en un sujeto. El agonista retinoide y el G-CSF o análogo de este pueden proporcionarse en una misma composición o en composiciones separadas. Se puede administrar una cantidad terapéuticamente eficaz del agonista retinoide y el G-CSF o análogo de este al sujeto de manera simultánea o secuencial. Las afecciones que pueden ser tratadas con los métodos y composiciones incluyen, de modo no taxativo, diversas formas de neutropenia e infecciones bacterianas. La invención también se refiere a métodos para determinar la eficacia de los tratamientos descritos en la presente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461941233P | 2014-02-18 | 2014-02-18 | |
PCT/US2015/016447 WO2015126989A1 (en) | 2014-02-18 | 2015-02-18 | Compositions and methods for treating neutropenia |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016010699A true MX2016010699A (es) | 2017-10-11 |
Family
ID=53878925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010699A MX2016010699A (es) | 2014-02-18 | 2015-02-18 | Composiciones y metodos para tratar neutropenia. |
Country Status (11)
Country | Link |
---|---|
US (1) | US10286039B2 (es) |
EP (1) | EP3107533A4 (es) |
JP (1) | JP2017508737A (es) |
KR (1) | KR20160113302A (es) |
CN (1) | CN106413701A (es) |
AU (1) | AU2015219038B2 (es) |
CA (1) | CA2937340C (es) |
MX (1) | MX2016010699A (es) |
RU (1) | RU2016136833A (es) |
WO (1) | WO2015126989A1 (es) |
ZA (1) | ZA201605109B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102083046B1 (ko) | 2012-06-07 | 2020-02-28 | 칠드런'스 하스피틀 로스 앤젤레스 | 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법 |
RU2016136833A (ru) | 2014-02-18 | 2018-03-22 | Чилдрен'З Хоспитал Лос Анджелес | Композиции и способы для лечения нейтропении |
CN107130026B (zh) * | 2017-05-15 | 2018-03-09 | 新疆医科大学第四附属医院 | 一种结直肠癌诊断和治疗效果评价相关的基因 |
CN111886008B (zh) * | 2017-10-18 | 2024-05-31 | 港大科桥有限公司 | 用于抗mers-冠状病毒治疗的组合物和方法 |
CN112390731B (zh) * | 2020-11-16 | 2022-11-25 | 成都大学 | 一种具有多靶点的维甲酸类衍生物及其制备方法与应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5691196A (en) | 1992-12-31 | 1997-11-25 | American Cyanamid Company | Recombinant nucleic acid containing a response element |
US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
JP2001506998A (ja) | 1996-12-19 | 2001-05-29 | アメリカン・サイアナミド・カンパニー | 好中球減少症の治療または抑制方法 |
EP1317537B1 (en) | 2000-09-08 | 2006-12-20 | Massachusetts Institute Of Technology | G-csf analog compositions and methods |
US7119061B2 (en) | 2002-11-18 | 2006-10-10 | Vicuron Pharmaceuticals, Inc. | Dalbavancin compositions for treatment of bacterial infections |
AU2003902308A0 (en) | 2003-05-14 | 2003-05-29 | Diagnose It Pty Ltd | A method and system for the monitoring of medical conditions |
AR044315A1 (es) | 2003-05-16 | 2005-09-07 | Kyowa Hakko Kogyo Kk | Agente para prevenir y/o tratar enfermedades acompañadas de alteraciones de tejidos que comprende un polipeptido |
EP1621191A1 (en) | 2004-07-29 | 2006-02-01 | Werner Bollag | Treatment of inflammatory diseases by RXR Antagonists |
WO2006020891A2 (en) | 2004-08-13 | 2006-02-23 | Anormed Inc. | Chemokine combinations to mobilize progenitor/stem cells |
PT1841432E (pt) | 2004-12-02 | 2010-10-25 | Venus Remedies Ltd | Composições para combater a resistência aos antibióticos mediada pela beta-lactamase usando inibidores da betalactamase úteis para injecção |
US20090111786A1 (en) | 2004-12-03 | 2009-04-30 | Glass Christopher K | Compounds that Prevent Macrophage Apoptosis and Uses Thereof |
EP2026778B1 (en) | 2006-05-16 | 2018-11-14 | Io Therapeutics, LLC | Rar antagonist or inverse agonist for use in the treatment of chemotherapy and/or radiation therapy side effects |
NZ580209A (en) | 2007-03-30 | 2011-11-25 | Tmrc Co Ltd | Tamibarotene capsule preparation |
WO2009070844A1 (en) | 2007-12-06 | 2009-06-11 | Csl Limited | Method of inhibition of leukemic stem cells |
US8580516B2 (en) * | 2008-09-05 | 2013-11-12 | University Of Chicago | Methods and compositions for direct detection of DNA damage |
JP2013508352A (ja) | 2009-10-19 | 2013-03-07 | ライラ ニュートラシューティカルズ | アセトゲニンを含む抽出物、フラクションおよび組成物ならびにそれらの応用 |
RU2446173C1 (ru) | 2010-08-13 | 2012-03-27 | Зао "Биокад" | Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе |
CN102380090A (zh) * | 2010-08-31 | 2012-03-21 | 健能隆医药技术(上海)有限公司 | G-csf二聚体在治疗嗜中性粒细胞减少症中的应用 |
EP2673358B1 (en) | 2011-02-08 | 2019-01-09 | FUJIFILM Cellular Dynamics, Inc. | Hematopoietic precursor cell production by programming |
WO2013169864A2 (en) | 2012-05-08 | 2013-11-14 | Lycera Corporation | TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE |
WO2013182652A1 (en) | 2012-06-06 | 2013-12-12 | Fondazione Telethon | Allosteric chaperones and uses thereof |
KR102083046B1 (ko) | 2012-06-07 | 2020-02-28 | 칠드런'스 하스피틀 로스 앤젤레스 | 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법 |
AU2014286688B2 (en) | 2013-07-04 | 2018-01-25 | Linak A/S | Actuator system |
RU2016136833A (ru) | 2014-02-18 | 2018-03-22 | Чилдрен'З Хоспитал Лос Анджелес | Композиции и способы для лечения нейтропении |
-
2015
- 2015-02-18 RU RU2016136833A patent/RU2016136833A/ru not_active Application Discontinuation
- 2015-02-18 MX MX2016010699A patent/MX2016010699A/es unknown
- 2015-02-18 CN CN201580009151.6A patent/CN106413701A/zh active Pending
- 2015-02-18 AU AU2015219038A patent/AU2015219038B2/en not_active Ceased
- 2015-02-18 JP JP2016552579A patent/JP2017508737A/ja active Pending
- 2015-02-18 US US15/119,339 patent/US10286039B2/en active Active
- 2015-02-18 WO PCT/US2015/016447 patent/WO2015126989A1/en active Application Filing
- 2015-02-18 EP EP15751576.8A patent/EP3107533A4/en not_active Withdrawn
- 2015-02-18 CA CA2937340A patent/CA2937340C/en active Active
- 2015-02-18 KR KR1020167025068A patent/KR20160113302A/ko unknown
-
2016
- 2016-07-21 ZA ZA2016/05109A patent/ZA201605109B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US10286039B2 (en) | 2019-05-14 |
RU2016136833A3 (es) | 2018-10-19 |
AU2015219038A1 (en) | 2016-08-04 |
KR20160113302A (ko) | 2016-09-28 |
AU2015219038B2 (en) | 2018-10-18 |
CN106413701A (zh) | 2017-02-15 |
WO2015126989A1 (en) | 2015-08-27 |
EP3107533A1 (en) | 2016-12-28 |
RU2016136833A (ru) | 2018-03-22 |
CA2937340A1 (en) | 2015-08-27 |
EP3107533A4 (en) | 2017-10-18 |
CA2937340C (en) | 2022-06-14 |
JP2017508737A (ja) | 2017-03-30 |
ZA201605109B (en) | 2017-09-27 |
US20170007672A1 (en) | 2017-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501646A1 (en) | Antimicrobial compounds and methods of making and using the same | |
PH12016500649A1 (en) | Combinations of histone deactylase inhibitors and immunomodulatory drugs | |
CA2909335C (en) | Fenfluramine for use in the treatment of dravet syndrome | |
MX2016009898A (es) | Tratamientos para acne resistente. | |
BR112016030541A2 (pt) | métodos para o tratamento de infecções fúngicas | |
WO2015023976A3 (en) | Selective grp94 inhibitors and uses thereof | |
PH12016500453A1 (en) | Antimicrobial compounds and methods of making and using the same | |
MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
MX2015010191A (es) | Metodos para tratar infecciones microbianas, incluyendo mastitis. | |
EA201691844A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
MX2016010699A (es) | Composiciones y metodos para tratar neutropenia. | |
MX363678B (es) | Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas. | |
PH12017500615A1 (en) | Ophthalmic composition comprising cyclosporine and trehalose | |
EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
WO2016094899A3 (en) | Treatment of hmgb1-mediated inflammation | |
PH12018502161A1 (en) | Methods of treatment for cholestatic and fibrotic diseases | |
MX2017011018A (es) | Inhibicion de la actividad de olig2. | |
WO2014152437A3 (en) | Methods of use for an antimicrobial peptide | |
MX2017014080A (es) | Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. | |
PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
EP3737384A4 (en) | METHODS AND COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CONDITIONS ASSOCIATED WITH ALPHA-SYNUCLEIN | |
EP3965799A4 (en) | SYNERGIC COMPOSITIONS AND METHODS OF TREATING INFECTIONS | |
MX2015013151A (es) | Métodos de tratamiento de disquinesia y trastornos relacionados. | |
WO2016191695A3 (en) | Treatments for obligately intracellular infections |